Oppenheimer has recently resumed Allogene Therapeutics Inc (ALLO) stock to Outperform rating, as announced on August 8, 2024, according to Finviz. Earlier, on May 31, 2024, Piper Sandler had initiated the stock to Overweight, setting a price target of $11. JMP Securities also reduced Mkt Perform rating. Additionally, Guggenheim reduced Neutral rating on January 5, 2024. Citigroup analysts, in their report published on December 8, 2023, also initiated Buy rating and set a price target of $7 for Allogene Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Allogene Therapeutics Inc (ALLO) Stock Trading Recap
On Monday, Allogene Therapeutics Inc (ALLO) stock saw a modest uptick, ending the day at $3.09 which represents a slight increase of $0.01 or 0.32% from the prior close of $3.08. The stock opened at $3.05 and touched a low of $2.99 during the day, reaching a high of $3.17. The volume of shares traded was 2.90 million exceeding the average volume of 1.96 million.
ALLO Stock Performance and Moving Averages
In recent trading, Allogene Therapeutics Inc (ALLO) stock price has shown some volatility, fluctuating 3.00% over the last five trades and 16.60% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 6.55%, and it has gained 31.49% in the previous three months. Currently, ALLO is trading at 9.56%, 12.57%, and -2.86% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, ALLO, a Healthcare sector stock, is trading -46.49% below its 52-week high but remains 53.73% above its 52-week low. The Average True Range (ATR) (14 days) of 0.22 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Allogene Therapeutics Inc’s Profitability and Valuation Ratios
Allogene Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -625246.51% and a profit margin of -659137.21%, with a gross margin of 6.55%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Allogene Therapeutics Inc’s market capitalization stands at $625.55 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 15638.64, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 1.4, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 33.91% of Allogene Therapeutics Inc (ALLO)’s shares, while financial institutions hold 66.18%.
